000K  utf8
1100  $c2021
1500  eng
2050  urn:nbn:de:gbv:8:3-2021-00875-0
2051  10.3389/fimmu.2021.765906
3000  Kouakanou, Léonce
3010  Brown, Christine E.
3010  Kabelitz, Dieter
3010  Peters, Christian
3010  Wang, Leo D.
4000  Vitamin C, From Supplement to Treatment$dA Re-Emerging Adjunct for Cancer Immunotherapy?  [Kouakanou, Léonce]
4209  Vitamin C (VitC), in addition to its role as a general antioxidant, has long been considered to possess direct anti-cancer activity at high doses. VitC acts through oxidant and epigenetic mechanisms, which at high doses can exert direct killing of tumor cells in vitro and delay tumor growth in vivo. Recently, it has also been shown that pharmacologic-dose VitC can contribute to control of tumors by modulating the immune system, and studies have been done interrogating the role of physiologic-dose VitC on novel adoptive cellular therapies (ACTs). In this review, we discuss the effects of VitC on anti-tumor immune cells, as well as the mechanisms underlying those effects. We address important unanswered questions concerning both VitC and ACTs, and outline challenges and opportunities facing the use of VitC in the clinical setting as an adjunct to immune-based anti-cancer therapies.
4950  https://doi.org/10.3389/fimmu.2021.765906$xR$3Volltext$534
4950  https://nbn-resolving.org/urn:nbn:de:gbv:8:3-2021-00875-0$xR$3Volltext$534
4961  https://macau.uni-kiel.de/receive/macau_mods_00002287
5051  610
5550  Cancer Biology
5550  Cancer Immunotherapies
5550  Car (Chimeric Antigen Receptor) T Cells
5550  Immune Checkpoint Therapy (Ict)
5550  Vitamin C (Ascorbic Acid)